Dimensional Fund Advisors LP Buys 225,588 Shares of NeoGenomics, Inc. $NEO

Dimensional Fund Advisors LP increased its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 9.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,674,335 shares of the medical research company's stock after purchasing an additional 225,588 shares during the period. Dimensional Fund Advisors LP owned approximately 2.05% of NeoGenomics worth $19,842,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in NEO. Loomis Sayles & Co. L P bought a new stake in shares of NeoGenomics in the fourth quarter valued at about $19,182,000. American Capital Management Inc. grew its holdings in shares of NeoGenomics by 120.9% during the third quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company's stock worth $18,105,000 after buying an additional 1,283,390 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in NeoGenomics by 69.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,218,727 shares of the medical research company's stock valued at $26,093,000 after buying an additional 912,788 shares during the last quarter. Trexquant Investment LP acquired a new stake in NeoGenomics in the 4th quarter valued at approximately $10,414,000. Finally, Cubist Systematic Strategies LLC bought a new stake in NeoGenomics in the 2nd quarter valued at approximately $6,071,000. Institutional investors own 98.50% of the company's stock.

NeoGenomics Stock Down 1.1%

NASDAQ:NEO opened at $15.56 on Friday. NeoGenomics, Inc. has a twelve month low of $5.62 and a twelve month high of $16.45. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of -38.90 and a beta of 1.74. The company has a quick ratio of 3.35, a current ratio of 3.60 and a debt-to-equity ratio of 0.48. The stock's 50 day moving average price is $13.28 and its two-hundred day moving average price is $10.79.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.03 by $0.02. NeoGenomics had a negative return on equity of 1.99% and a negative net margin of 6.77%.The company had revenue of $201.66 million during the quarter, compared to the consensus estimate of $196.93 million. During the same quarter in the prior year, the firm posted $0.03 EPS. The firm's revenue for the quarter was up 11.2% compared to the same quarter last year. Equities research analysts expect that NeoGenomics, Inc. will post -0.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Weiss Ratings raised shares of NeoGenomics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, July 14th. Leerink Partners raised shares of NeoGenomics from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $12.00 to $25.00 in a research report on Wednesday, April 29th. Zacks Research upgraded shares of NeoGenomics from a "hold" rating to a "strong-buy" rating in a report on Friday, July 31st. Needham & Company LLC raised their target price on shares of NeoGenomics from $15.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. Finally, Craig Hallum reaffirmed a "buy" rating and issued a $19.00 target price on shares of NeoGenomics in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $16.71.

Insider Activity at NeoGenomics

In other news, Director Lynn A. Tetrault sold 5,307 shares of the business's stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $11.29, for a total transaction of $59,916.03. Following the transaction, the director directly owned 91,422 shares in the company, valued at $1,032,154.38. The trade was a 5.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.10% of the stock is currently owned by company insiders.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company's core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source